Mod GRF 1-29 & GHRP-6 – 10MG
$83.00
Discount per Quantity
Quantity | Discount | Price |
---|---|---|
5 - 8 | 5% | $78.85 |
9 + | 10% | $74.70 |
Mod GRF 1-29 (CJC-1295) & GHRP-6 Blend
GHRP-6 (Growth Hormone Releasing Peptide-6) is a hexapeptide that creates a signal in the body telling it to release more Growth Hormone. Technically, it is a ghrelin mimetic or growth hormone secretagogue (GHS). It contains six amino acids and is known as a hexapeptide. Many studies have shown what GHPR-6 can do, it can help increase GH levels which in turn promotes an increase in IGF-1 as well as helping reduce growth hormone deficiency and muscle wasting (cachexia).
Mod GRF 1-29, also known as CJC-1295 without DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone designed to stimulate the release of growth hormone. Consists of 29 amino acids similar to growth hormone releasing peptides (GHRPs) and is a GHRP analogue being tetrasubstitued as GRF (1-29). This is the smallest fragment of the GHRH peptide sequence still having the full ability to bind to growth hormone receptors.
Researchers speculate that Mod GRF 1-29 and GHRP-6 function synergistically to stimulate growth hormone secretion and promote increased expression of insulin-like growth factor-1 (IGF-1) through action at the GHRH-receptors and ghrelin receptors, respectively. Mod GRF 1-29 seems to associate with the GHRH receptors (GHRH-R) on somatotroph cells of anterior pituitary. Mod GRF 1-29 binds to receptors, and may indeed induce intracellular signaling cascades. A possible pathway activated is likely the adenylyl cyclase thus eventually end as ATP (adenosine triphosphate) acting as precursor of cAMP (cyclic adenosine monophosphate). It is possible that the increase in cAMP levels can result in the activation of protein kinase A (PKA). The phosphorylation of several proteins in response to the activation, i.e., voltage-dependent calcium channels on the cell membrane.
Phosphorylation initiates the opening of these calcium channels that then permits Ca2+ ions to flow into the somatotropic cells. An increase in intracellular calcium levels is proposed to be involved in the subsequent stages of GH release. Another speculation is that increased intracellular calcium levels may activate the secretory vesicles located in the somatotroph cells to release growth hormone into the circulation. In contrast, GHRP-6 has also been documented to bind to the ghrelin receptor (GHS-R1a) and activate it potentially resulting in the release of growth hormone. GHRP-6 is said to be a synthetic hexapeptide that possesses a great affinity for the GHS-R1a. GHRP-6 stimulates a conformational change,not certainly leading to activation upon binding.
This stimulation mimics the biological effects of GHRP-6 and mirrors in part that of other growth hormone-releasing peptides such as ghrelin, which thus binds to the same receptor known as GHS-R1a. One example of a putatively activated signaling pathway is the phospholipase C (PLC) pathway, which might cause the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). It is thought to activate IP3 which then in turn creates intracellular signalling mechanisms associated with the recurring release of calcium from intracellular stores, possibly leading to an intercellular increase in the levels of calcium. This rise in Ca levels might be involved in the GH release from the pituitary.
THE CONTENT ON THIS WEBSITE IS STRICTLY INFORMATIONAL. IT IS NOT INTENDED TO BE TAKEN AS MEDICAL ADVICE OR AS A SCIENTIFIC PUBLICATION.
None of the products have been evaluated by The Food and Drug Administration, and are not for medical use. Their use in human or animal subjects is strictly prohibited by law, and they are available here only for in-vitro research purposes, by licensed professionals. By purchasing from this site, you agree to comply with our Terms and Conditions.